Researchers recently explored how S1PR1 expression in SLE influences disease progression and immune cell trafficking. Systemic lupus erythematosus (SLE) remains a complex autoimmune condition. Consequently, scientists focus on S1PR1 because it acts as a key regulator. Specifically, the study evaluated S1PR1 across various B cell subsets.

Clinical Significance of S1PR1 Expression in SLE

Notably, the results showed significant differences. While intracellular levels increased in all subsets, surface levels decreased on aNAV B cells. Conversely, antibody-secreting cells (ASCs) showed surface upregulation. Furthermore, clinicians found that downregulated surface S1PR1 expression in SLE on aNAV B cells correlates with disease activity. Specifically, lower levels associate with lupus nephritis (LN) and higher SLEDAI-2K scores. Additionally, researchers noted a significant negative correlation with the erythrocyte sedimentation rate (ESR).

In addition, the study examined the CXCR3 chemokine receptor. Although most subsets showed correlations, aNAV B cells did not. Therefore, chronic activation likely leads to S1PR1 internalization. Thus, this process alters how cells recirculate. Similarly, it impacts how cells respond to target tissue signals. Moreover, these findings suggest S1PR1 serves as a vital marker for monitoring lupus activity.

Frequently Asked Questions

How does S1PR1 expression relate to lupus nephritis?

Downregulated surface expression of S1PR1 on activated naive B cells strongly correlates with the presence of active lupus nephritis. This suggests that receptor changes may drive B cell migration into renal tissues.

Why does surface S1PR1 decrease in SLE patients?

Chronic activation in SLE leads to the desensitization or internalization of the S1PR1 receptor. This mechanism reduces the receptor's presence on the cell surface, affecting how B cells move through the body.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Tianpothong P et al. Aberrant sphingosine-1-phosphate receptor 1 expression on activated naive B cells associated with disease activity and lupus nephritis in systemic lupus erythematosus. Arthritis Res Ther. 2026 May 14. doi: 10.1186/s13075-026-03829-3. PMID: 42135812.

2. Sun J et al. S1P/S1PR signaling pathway advancements in autoimmune diseases. PMC. 2024.

3. Wang L et al. Exploratory Pilot Study on the Serum Ceramide (16:0) to Sphingosine-1-Phosphate Ratio as a Potential Indicator of Lupus Nephritis and Disease Activity. MDPI. 2025.